Serum level of hepcidin in cirrhotic patients as a marker for hepatocellular carcinoma
Abstract Background People all around the world are affected by primary liver cancers like hepatocellular carcinoma (HCC), which is usually associated with cirrhosis. Early HCC detection is crucial for better prognosis, but effective biomarkers are still needed. Hepcidin, a hormone-regulating iron h...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2024-02-01
|
| Series: | Egyptian Liver Journal |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s43066-023-00307-2 |
| _version_ | 1827328627704856576 |
|---|---|
| author | Khaled Mahmoud Mohiedeen Mona Moustafa Tahoon Christina Samir Sadek Hanna Mohamed Adel Abdel Aziz |
| author_facet | Khaled Mahmoud Mohiedeen Mona Moustafa Tahoon Christina Samir Sadek Hanna Mohamed Adel Abdel Aziz |
| author_sort | Khaled Mahmoud Mohiedeen |
| collection | DOAJ |
| description | Abstract Background People all around the world are affected by primary liver cancers like hepatocellular carcinoma (HCC), which is usually associated with cirrhosis. Early HCC detection is crucial for better prognosis, but effective biomarkers are still needed. Hepcidin, a hormone-regulating iron homeostasis, has been implicated in liver diseases. In this study, blood hepcidin levels were evaluated in cirrhotic individuals as a possible biomarker for HCC. Methods There were three groups involved in this case-control study: cirrhotic patients with no HCC (group I), cirrhotic patients diagnosed with HCC (group II), and healthy controls (group III). Clinical and laboratory data, such as those from tests indicating the liver function, hepcidin levels, and imaging, were all analyzed using a number of statistical tests. Results When compared to those with cirrhosis, serum hepcidin levels were significantly lower in HCC patients, but there was no significant difference statistically between the two studies involved: cirrhotic groups and the controls. Serum alpha-fetoprotein (AFP) was also significantly greater in HCC patients. Conclusions The start and progression of liver diseases, such as HCC in cirrhotic people, appear to be influenced by hepcidin. It can be utilized as a potential HCC biomarker when cirrhotic liver is present, despite the fact that it cannot be used to diagnose cirrhosis by itself. |
| first_indexed | 2024-03-07T15:20:14Z |
| format | Article |
| id | doaj.art-b3df7b1c2d084f978754a0be9127ab5c |
| institution | Directory Open Access Journal |
| issn | 2090-6226 |
| language | English |
| last_indexed | 2024-03-07T15:20:14Z |
| publishDate | 2024-02-01 |
| publisher | SpringerOpen |
| record_format | Article |
| series | Egyptian Liver Journal |
| spelling | doaj.art-b3df7b1c2d084f978754a0be9127ab5c2024-03-05T17:44:00ZengSpringerOpenEgyptian Liver Journal2090-62262024-02-011411810.1186/s43066-023-00307-2Serum level of hepcidin in cirrhotic patients as a marker for hepatocellular carcinomaKhaled Mahmoud Mohiedeen0Mona Moustafa Tahoon1Christina Samir Sadek Hanna2Mohamed Adel Abdel Aziz3Department of Tropical Medicine, Faculty of Medicine, Alexandria UniversityDepartment of Clinical and Chemical Pathology, Faculty of Medicine, Alexandria UniversityDepartment of Tropical Medicine, Faculty of Medicine, Alexandria UniversityDepartment of Tropical Medicine, Faculty of Medicine, Alexandria UniversityAbstract Background People all around the world are affected by primary liver cancers like hepatocellular carcinoma (HCC), which is usually associated with cirrhosis. Early HCC detection is crucial for better prognosis, but effective biomarkers are still needed. Hepcidin, a hormone-regulating iron homeostasis, has been implicated in liver diseases. In this study, blood hepcidin levels were evaluated in cirrhotic individuals as a possible biomarker for HCC. Methods There were three groups involved in this case-control study: cirrhotic patients with no HCC (group I), cirrhotic patients diagnosed with HCC (group II), and healthy controls (group III). Clinical and laboratory data, such as those from tests indicating the liver function, hepcidin levels, and imaging, were all analyzed using a number of statistical tests. Results When compared to those with cirrhosis, serum hepcidin levels were significantly lower in HCC patients, but there was no significant difference statistically between the two studies involved: cirrhotic groups and the controls. Serum alpha-fetoprotein (AFP) was also significantly greater in HCC patients. Conclusions The start and progression of liver diseases, such as HCC in cirrhotic people, appear to be influenced by hepcidin. It can be utilized as a potential HCC biomarker when cirrhotic liver is present, despite the fact that it cannot be used to diagnose cirrhosis by itself.https://doi.org/10.1186/s43066-023-00307-2Hepatocellular carcinoma (HCC)CirrhosisHepcidinBiomarkerEarly detection |
| spellingShingle | Khaled Mahmoud Mohiedeen Mona Moustafa Tahoon Christina Samir Sadek Hanna Mohamed Adel Abdel Aziz Serum level of hepcidin in cirrhotic patients as a marker for hepatocellular carcinoma Egyptian Liver Journal Hepatocellular carcinoma (HCC) Cirrhosis Hepcidin Biomarker Early detection |
| title | Serum level of hepcidin in cirrhotic patients as a marker for hepatocellular carcinoma |
| title_full | Serum level of hepcidin in cirrhotic patients as a marker for hepatocellular carcinoma |
| title_fullStr | Serum level of hepcidin in cirrhotic patients as a marker for hepatocellular carcinoma |
| title_full_unstemmed | Serum level of hepcidin in cirrhotic patients as a marker for hepatocellular carcinoma |
| title_short | Serum level of hepcidin in cirrhotic patients as a marker for hepatocellular carcinoma |
| title_sort | serum level of hepcidin in cirrhotic patients as a marker for hepatocellular carcinoma |
| topic | Hepatocellular carcinoma (HCC) Cirrhosis Hepcidin Biomarker Early detection |
| url | https://doi.org/10.1186/s43066-023-00307-2 |
| work_keys_str_mv | AT khaledmahmoudmohiedeen serumlevelofhepcidinincirrhoticpatientsasamarkerforhepatocellularcarcinoma AT monamoustafatahoon serumlevelofhepcidinincirrhoticpatientsasamarkerforhepatocellularcarcinoma AT christinasamirsadekhanna serumlevelofhepcidinincirrhoticpatientsasamarkerforhepatocellularcarcinoma AT mohamedadelabdelaziz serumlevelofhepcidinincirrhoticpatientsasamarkerforhepatocellularcarcinoma |